Drugs / Protaphane
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Protaphane | — | 2002-10-07 | europa.eu ↗ |
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT01649466 Comparator | Aug 2012 → Oct 2013 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | Mixed |
| Phase 4 | NCT01269996 Comparator | May 2011 → Jul 2014 | type 2 diabetes mellitus | Chinese University of Hong Kong | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Protaphane | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01649466 ↗ |
| Modality | Protein / enzyme biologic | “supplementary intermediate-acting insulin (Protaphane) injection” NCT01269996 ↗ |
| Route | Other | “supplementary intermediate-acting insulin (Protaphane) injection” NCT01269996 ↗ |